H.R. 2339
Referred to CommitteeProtecting American Lungs and Reversing the Youth Tobacco Epidemic Act of 2020
Latest Action
Received in the Senate and Read twice and referred to the Committee on Finance.
3/2/2020 • Senate
Summary
Protecting American Lungs and Reversing the Youth Tobacco Epidemic Act of 2020
This bill revises requirements related to the safety, sale, and advertisement of tobacco products, including electronic nicotine delivery systems (e.g., e-cigarettes, e-hookah, e-cigars, and vape pens).
Among other requirements, the bill
- requires the Food and Drug Administration (FDA) to implement regulations to require color graphics on the labeling of cigarette packages, depicting the negative health consequences of smoking;
- requires the FDA to apply regulations on tobacco products to all tobacco products, including e-cigarettes;
- generally prohibits the retail online sale of tobacco products, including electronic nicotine delivery systems;
- prohibits flavors other than tobacco in a tobacco product;
- prohibits the use of flavored products in an electronic nicotine delivery system, except in specified circumstances;
- increases the user fees that the FDA collects from manufacturers and importers;
- directs the FDA to regulate products containing nicotine not made or derived from tobacco plants (including nicotine from chemical synthesis, recombinant genetic technology, or extraction from non-tobacco plants);
- imposes an excise tax on nicotine that has been extracted, concentrated, or synthesized;
- provides funding through FY2025 to support public education regarding tobacco regulation, public awareness regarding the harms associated with tobacco use, outreach to medically underserved communities regarding tobacco-use prevention and cessation, research grants related to tobacco-use prevention and cessation, and grants to health centers for tobacco-use cessation treatment;
- establishes and provides funding through FY2025 for a demonstration grant program to develop strategies for smoking cessation (including of the use of menthol-flavored tobacco products) in medically underserved communities;
- beginning in 2024, waives coinsurance under Medicare for colorectal-cancer screening tests;
- specifies that a health insurance plan may still be treated, for certain tax-deduction purposes, as a high-deductible plan even if it does not have a deductible for certain inhalers or nebulizers;
- exempts certain cigars from premarket review requirements;
- increases civil penalties for certain violations of restrictions on the sale of tobacco products; and
- requires the Government Accountability Office to study e-cigarettes.
Passed House • 2/28/2020
Topics & Subjects
CBO Cost Estimates (1)
Amendments (1)
This bill has 1 amendment proposed or adopted.
View all amendments on Congress.govCongressional Votes (2)
On Passage
February 28, 2020
On Motion to Recommit with Instructions
February 28, 2020
Related Federal Spending
Sponsor & Cosponsors (127)
Party Breakdown
Sponsor
Cosponsors (126)
Bill Journey
Originated in the House
Introduced
April 18, 2019
Committee Review
October 16, 2019
Floor Debate
February 28, 2020
Passed Chamber
February 27, 2020
Other Chamber
President
Failed
February 28, 2020
Text Versions (4)
Committee Reports (1)
Related Bills (6)
S. 3174
Reversing the Youth Tobacco Epidemic Act of 2020
H.Res. 866
Providing for consideration of the bill (H.R. 2339) to amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products, and for other purposes.
H.R. 4716
I CAN Act
H.R. 4742
Protecting American Lungs Act of 2019
S. 3223
Resources to Prevent Youth Vaping Act
H.R. 1570
Removing Barriers to Colorectal Cancer Screening Act of 2020